



# DRUG DISCOVERY 2022

DRIVING THE NEXT LIFE SCIENCE  
REVOLUTION

---

4TH & 5TH OCTOBER 2022

ExCeL, LONDON

#ELRIG

#ELRIGDD22

#DRUGDISCOVERY

 [elrig.org](https://elrig.org)

 [@ELRIG\\_UK](https://twitter.com/ELRIG_UK)

 [elrig](https://www.linkedin.com/company/elrig)

# WELCOME TO DRUG DISCOVERY 2022

## A MESSAGE FROM THE CHAIR OF ELRIG, MELANIE LEVERIDGE



On behalf of ELRIG I would like to welcome you to the 16th Drug Discovery meeting, Drug Discovery 2022!

The Drug Discovery conference is the flagship of all ELRIG events and marks the pinnacle of the ELRIG yearly meetings calendar, by bringing together the drug discovery life science community, for a festival of cutting-edge science and technology. I am delighted that once again we can come back together at Drug Discovery 2022 for a celebration of drug discovery.

This year's theme of "Driving the Next Life Science Revolution", is a challenge to us all. As a community we joined together to successfully ease a global pandemic and this year at Drug Discovery 2022, we should ask ourselves as a community "What can we do next?". We as a community have been outstanding in 2020 and 2021 and Drug Discovery 2022, aims to ensure we continue to be so, by providing an impressive scientific programme free-of-charge to attend.

There are numerous highlights that we will announce at the meeting:

- During my introduction, I will talk about ELRIG's success in the year as well as our full calendar of events for 2023 so you can hold the dates in your diaries now!
- We welcome 2 fantastic plenary keynote speakers, Professor Molly Stevens from Imperial College London and Rab Prinjha, from GlaxoSmithKline.
- For the first time we are running ELRIG's Tech Theatre, which is supported by DDW, where we will showcase a series of more applied seminars on automation in drug discovery.
- Mark Soave, the Chair of ELRIG's Early Career Professional (ECP) Work Group has created a series of workshops and networking events specifically for the ECP community including the now famous 'Network like a boss' session.

- We welcome our partner organisations, the British Pharmacological Society (BPS), the Royal Society of Chemistry (RSC) and the Society of Laboratory Automation and Screening (SLAS), who have all contributed to the programme this year. During the meeting we will also showcase the winners of the SLAS Innovation AveNEW awards.
- We will present this year's ELRIG's Impact Award, sponsored by Elemental Machines, to Shaun Pennington PhD MRSB from the Liverpool School of Tropical Medicine and you will have the opportunity to hear him speak about his work.

As you can see there is lots going on and it promises to be a fantastic two days.

The success of ELRIG is dependent upon the many volunteers who give their time freely to create our meetings and other events as well as the vendor community who support our organisation, by taking sponsorship opportunities at each meeting. I would like to thank the science committee, session chairs, speakers, and exhibitors for their contributions to this event. The volunteers and vendors are supported by an outstanding

# ABOUT ELRIG

The European Laboratory Research & Innovation Group (ELRIG) is a leading European not-for-profit organization that exists to provide outstanding scientific content to the life science community. The foundation of the organisation is based on the use and application of automation, robotics and instrumentation in life science laboratories, but over time, we have evolved to respond to the needs of biopharma by developing scientific programmes that focus on cutting-edge research areas that have the potential to revolutionize drug discovery.

Comprising a global community of over 12,000 life science professionals, participating in our events, whether it be at one of our scientific conferences or one of our networking meetings, will enable any of our community to exchange information, within disciplines and across academic and biopharmaceutical organisations, on an open access basis, as all our events are free-of-charge to attend!

## OUR VALUES

Our values are to always ensure the highest **quality of content** and that content will be made readily **accessible to all**, and that we will always be an **inclusive** organisation, serving a **diverse scientific network**. In addition, ELRIG will always be a **volunteer led** organisation, run by and for **the life sciences community**, on a **not-for-profit** basis.

## OUR PURPOSE

ELRIG is a company whose purpose is to bring the life science and **drug discovery** communities together to **learn, share, connect, innovate and collaborate**, on an **open access** basis. We achieve this through the provision of world class conferences, networking events, webinars and digital content.

## GOVERNANCE

ELRIG's board is comprised of volunteers from it's community, who either work in biopharma, CRO's, academia or with vendor companies. The board is steered by the General Committee, who act as a direct connection to the community and thus is comprised of a diverse group of people. The board delegates it's tasks to a series of work groups, who work with the Operational Team to ensure ELRIG achieves it's objectives. Current work groups are:

- Early Career Professionals
- Marketing Communications
- Networking & Webinars
- People & Culture
- Publications
- Science Strategy
- Vendor Outreach

## STRATEGIC PILLARS



### EVENTS

Deliver UK leading events, showcasing cutting edge science and technology, that are accessible to all.



### EQUALITY, DIVERSITY & INCLUSIVITY

Promote inclusivity, engagement and collaboration, in our diverse community.



### PRESENCE & AWARENESS

Expand and enhance our digital presence.



### SUSTAINABILITY

Drive an open and transparent organisation, with a focus on delivery excellence and financial sustainability.

# WELCOME TO DRUG DISCOVERY 2022

As Conference Directors it is our great pleasure to welcome you back to London for Drug Discovery 2022!

This year's theme "Driving the Next Life Science Revolution", was chosen to challenge us all to build on the scientific momentum created throughout the period of the pandemic, by providing a platform for the whole drug discovery community to meet at Europe's largest free-to-attend life science event, where over 1500 delegates of ELRIG's community may:

- Listen to over 50 world-class speakers and almost 40 technology presentations from the life sciences vendor community.
- Read and discuss over 120 cutting-edge scientific posters talking about a multitude of topics in drug discovery.
- Visit over 120 exhibitors, who will display their latest and most innovative technologies in the exhibition hall.

All of this content is taking place over 2 days at ExCel, an outstanding conference and event venue in London.

Our organising committee and session chairs have been working hard since late 2021 and thanks to them we have again been able to assemble a world-class lineup of scientific speakers, with 50 talks taking place across 4 tracks over 2 days.

We encourage you to engage in as much of the science as you possibly can and to take full advantage of the exhibitors' expertise and knowledge to enhance your own research. The vendor presence at ELRIG ensures that these conferences are of minimal cost to attendees, so please show your appreciation by visiting the booths and asking as many probing and difficult questions of their technology as possible. With these interactions they are better equipped to supply us with the tools of the future to make the next set of discoveries.

We would like to thank the ELRIG Board and General Committee for their support in assembling this world-class scientific programme. We would also like to thank the ELRIG Operational Team, for patiently shepherding ourselves and the Session Chairs through the organising process. Without their help, together with the all the other volunteers, this meeting would not be possible.

Finally, this meeting would be nothing without you, the meeting delegate. We thank you in advance for your participation and look forward to connecting with you over the next couple of days. As always, we welcome your feedback on how we can further improve the agenda to ensure the growth and success of ELRIG's Drug Discovery for the future.

Have fun in London and enjoy the opportunity to discuss emerging science within a vibrant and educational environment!



**Dr Katie Chapman**  
Discovery Biology Director,  
VC funded Biotech Company



**Dr Simon Chell**  
Executive Director,  
Discovery Biology, AstraZeneca



**Dr Jon Hutchinson**  
Scientific Leader,  
GlaxoSmithKline



**Prof Simon Ward**  
Director of the Medicines Institute,  
Cardiff University

# DRUG DISCOVERY 2022 SESSION CHAIRS

## HIGH CONTENT IMAGING IN DRUG DISCOVERY



Sian Lewis  
MSD



Michael Howell  
The Francis Crick Institute



Allan Jordan  
Sygnature Discovery



Sarah Skerrat  
CHARM Therapeutics

## CELL & GENE THERAPY



Chris Herring  
Adaptimmune



Claire Dobson  
AstraZeneca



Anna Morgan  
Physiology & Pharmacology,  
Kingston University



Simon Pitchford  
King's College London

## DRUG DISCOVERY AND DEVELOPMENT IN COPD

## DEVELOPMENTS IN PRECLINICAL MODELS



Lisa Mohamet  
GlaxosmithKline



Sam Barichiev  
AstraZeneca



Kathryn Chapman  
Milner Therapeutics Institute



Dave Powell  
LifeArc

## INNOVATION THROUGH PARTNERSHIP

## FRONTIERS OF CHEMISTRY APPLIED TO DRUG DISCOVERY



Katie Lim  
Royal Society of  
Chemistry



Becky Garton  
Royal Society of  
Chemistry



A. Ganesan  
University Of East  
Anglia



Mary Wheldon  
University of Dundee



Martin Swarbrick  
Ryvü Therapeutics

## ADVANCEMENTS IN SCREENING AND AUTOMATION



Mario Richter  
AbbVie Deutschland  
GmbH & Co. KG



Kirsten Tschapalda  
Roche



# INFORMATION FOR PARTICIPANTS

---

## REGISTRATION

To help keep Drug Discovery 2022 a safe space, we require the following from all attendees:

1. Pre-registration for the meeting is essential. Please register at [elrig.org](http://elrig.org) and enter our EventFlo registration system (*if you wish to, you may choose a pro-noun, which will be printed on your badge*).
2. To ensure we minimize the risk of spreading COVID, please ensure that you have had at least two vaccinations against the COVID virus and that you are not presenting with any of the symptoms. At registration you may be asked to present your COVID passport, or a document issued by your local government showing you have been double vaccinated. Once you have entered the venue, you may wear a mask if you wish, but this is not compulsory.  
  
Please be aware that we expect the meeting to be completely full, so social distancing in the exhibition area and auditorium will not be possible.
3. Please observe our safe space guidelines:  
At ELRIG we want all our meeting participants, whether the meeting is face-to-face or on-line, to enjoy, participate in and contribute to the event. We are therefore dedicated to providing a harassment-free experience for all event participants involved in its activities and meetings. ELRIG does not accept harassment or intimidation of ELRIG participants in any form whether verbal, physical, or written (including on social media or by email).

Harassment includes, but is not limited to:


1. Offensive or unwanted conduct on the basis of age, disability, gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, sex or sexual orientation which has the purpose or effect of violating dignity or creating an intimidating, hostile or degrading environment.
2. Use of sexualised or other inappropriate images or unwelcome sexualised content, inappropriate physical contact, unwelcome sexual attention or stalking.
3. Sustained interruption of speakers or those asking questions.
4. Unwanted photography or filming.

Intimidation includes, but is not limited to:

1. Making threats.
2. Bullying.
3. Personal attacks.

Participants who do not adhere to these rules will be asked to stop and expected to comply immediately. Participants may be removed from any meeting or communications at the discretion of ELRIG's management if this behaviour continues. If you are being harassed/intimidated, notice that someone else is being harassed/intimidated, or have any other concerns, please contact any of the ELRIG management team immediately. They will be able to step in to remove you or others from a chain of communication, if this is the preferred action, and can also facilitate a discussion or mediation. If you wish, you may also nominate someone else to support facilitating any mediation or as an observer to this process.

Please note that ELRIG authorised photographs and videos will be taken throughout the duration of the meeting, which may then be used for promotional purpose after the event. If you do not wish your image to be used, please let the organisers know. The taking of your own photographs or making your own recordings is strictly forbidden, unless it is needed to help your accessibility to the presentations. The event is cashless and free! All beverages and food served is freely available to all who attend.



# INFORMATION FOR PARTICIPANTS

---

## WIFI

ExCeL have free, fast WiFi which is suitable for browsing, social media, and email.

When you arrive at the venue, you need to sign in to 'ExCeL free Wi-Fi' You can also join via LinkedIn, Facebook, or Twitter.

## PRAYER ROOM

The prayer room can be accessed through the grey door next to the S9 entrance on the boulevard.

## FAMILY ROOM

The family room can be found by S9. Inside has two changing mats, chairs for breastfeeding, a microwave to heat up baby food and a bottle warmer. It also contains a sink and toilet.

## QUIET ROOM

The quiet room can be accessed through the grey door next to the S9 entrance on the boulevard.

## DISABLED PARKING

Disabled parking bays are spread across the car park.

## DISABLED TOILETS

The disabled toilets are located at the back of the Hall N4 and between halls N10/N11 and Between halls S9/S10 and level 0.

## WATER REFILL STATIONS

There are four water refill stations located by the East and West Entrances as well as by the halls S4 and S7.

## CLOAKROOMS

Venue cloakrooms are open during event hours and are provided complimentary (subject to availability). The cloakrooms are located on level 0 (down the stairs, in between hall entrances N4 & S4) and at the east end of the venue on level 0.

## PHONE CHARGING

If you have low battery charge, use one of our charging points. ChargeBox mobile phone charging points for all major brands are at the east and west information desks.

## ELRIG MOBILE APP

Download the free ELRIG app and access all our conference information, programme and more from your phone or tablet.

- View the event programme
- View presentation and poster abstracts
- View speaker profiles
- View the exhibitor guide
- View the delegate and exhibitor list
- Organise your day with your own favourites list
- Share your profile as vCard and QR Code and scan exhibitor QR code information tags
- Network – contact delegates, other exhibitors and speakers easily through opt-in directories and integration with Linked-In, Twitter and Facebook

You can download the ELRIG app by visiting the app store appropriate to your tablet or smart phone, scanning the QR code below or visiting the ELRIG website: [elrig.org/mobile-app](http://elrig.org/mobile-app)



ELRIG volunteer staff are wearing distinctive red t-shirts. If you need help on any issue, ask a Red-Shirt!

# PLENARY KEYNOTE SPEAKERS

---



**Molly Stevens**

Professor of Biomedical Materials and Regenerative Medicine, Imperial College London

## NEW TECHNOLOGIES FOR THE DESIGN AND CHARACTERISATION OF NANOTECHNOLOGY MEDIATED THERAPEUTICS

4th October 2022, 09.35

Auditorium 1

In this talk I will discuss highlights of our nanomedicine portfolio including nanosensors for diagnosing and monitoring infectious and non-communicable diseases, nanomimicking approaches for virus and parasite host cell entry inhibition recently demonstrated for malaria, HSV-2 and SARS-CoV-2, and high molecular weight polymer carriers for enhanced delivery of saRNA therapeutics. I will present advances in Raman spectroscopy for high-throughput label-free characterization of single nanoparticles (SPARTA™) that allow us to integrally analyse a broad range bio-nanomaterials such as polymer particles, liposomes and extracellular vesicles without any modification.

SPARTA™ has become an integral tool for the design of nanotherapeutics, with recent examples including DOPC-containing lipid nanoparticles for nucleic acid delivery and dendrimersome-based systems for controlled delivery of antibacterial drugs, and for profiling extracellular vesicles (EVs) for detection of breast cancer through a minimally invasive liquid biopsy. I will also discuss our cell interfacing nanoneedle platforms for multiplexed intracellular biosensing at sub-cellular resolution and modulation of biological processes. I will explore how these versatile technologies can be applied to transformative biomedical innovations.



**Rabinder Prinjha**

VP, Head of Immunology Research Unit, GlaxoSmithKline

## GENOMIC SCIENCES IN IMMUNOLOGY – STRATEGIES FOR FINDING FUTURE DRUG TARGETS THROUGH GENETICS, FUNCTIONAL GENOMICS AND IMMUNOPHENOTYPING

5th October 2022, 09.05

Auditorium 1

One of the most critical decisions in the discovery of future medicines is the selection of the right target. Astonishing progress resulting from sustained investment in academia, pharma and PPP consortia have enabled a step-change in our ability to access and use human genetics, genomics and immune-system level data to inform these target selection decisions. Rab will

talk about the importance and power of generating high quality human data then integrating these data-sets to enable the prioritisation of hits from genetics and functional genomics screens. He will illustrate the potential portfolio level impact and the remaining challenges of working with very novel targets discovered through this genetics informed immunology strategy.



# ELRIG'S EQUALITY DIVERSITY AND INCLUSION AIMS AND GUIDING PRINCIPLES

---

## OUR AIMS

- ELRIG will strive for cultural change, both for itself and the ELRIG community
- Rather than a policy we have developed the ELRIG Community's Guiding Principles
- We will communicate the journey and the conclusions
- The process and implementation of outcomes will be transparent
- Data and the ELRIG community will guide action
- Mechanisms will be put in place to ensure that accessibility is maximised at all events
- Guiding principles will be embedded in governance and all Work Groups daily activities

## OUR GUIDING PRINCIPLES

We will promote equality, by welcoming all to all our events and will be inclusive, by removing barriers to access, and that our events will represent the diversity of the ELRIG community.

### OUR EQUALITY PRINCIPLE IS:


We will ensure that all are welcome by: profiling the demographics of attendees by segment, age, ethnicity, disability and gender, monitoring and ensuring that no one group is favoured nor excluded and act to ensure equal outcomes and opportunities for the entire ELRIG community.

### OUR DIVERSITY PRINCIPLE IS:

We will strive for gender balance at our events, by ensuring that the diversity mix of our speakers represents the diversity of our delegates, and that the diversity mix of our delegates represents the diversity of the ELRIG community, as well as ensuring that scientific content reflects the diversity of the ELRIG community.

### OUR INCLUSIVITY PRINCIPLE IS:

We will ensure that accessibility is maximised at all events, by removing barriers to those with disabilities, limits on finances, caring and parental responsibilities, religious needs, geographical location and other requirements. To ensure our principles remain relevant, we will solicit, monitor, and report to the ELRIG community and act upon relevant feedback during and after events to maintain accessible and safe spaces in which to collaborate.



# EARLY CAREER PROFESSIONAL ACTIVITIES



"Early Career Professionals (ECPs) are undergraduates, postgraduates or scientists that are just setting out on their career path in any type of academic, charitable, or industrial institution. ECPs are critical contributors to the ELRIG community, bringing new science, fresh ideas, and energy to the life science industry and the ECP Impact award looks to highlight our future leaders. We have multiple ECP activities starting with the Award winner." - Mark Soave, Senior Scientist - OMass Therapeutics and Early Career Professional Work Group Leader



## ELRIG'S EARLY CAREER PROFESSIONAL IMPACT AWARD 2022

Shaun Pennington, Senior Research Associate, Liverpool School of Tropical Medicine

### Pandemic response: accessible BSL3 platforms for drug discovery

5th October 2022, 09.55

Auditorium 1



Soon after SARS-CoV-2 was recognised as a pandemic threat, we set out to establish a pre-clinical pipeline at the Liverpool School of Tropical Medicine.

A high-throughput, low-cost method for the assessment of compounds targeting SARS-CoV-2 was quickly validated. This method was deployed to screen thousands of compounds and was used to study synergistic drug interactions. We have continued to develop more advanced models of infection, using various host-cell types as well as advanced, dynamic-flow organoid infection model systems. In parallel, we have also developed an advanced model of transmission to assess the activity of technologies targeting aerosolised SARS-CoV-2.

Through partnership with the Infection Innovation Consortium (iiCON), hosted at Liverpool School of Tropical Medicine, we have been able to provide industrial partners, as well as small and medium-sized enterprises (SMEs), with access to these experimental platforms. This model for access has provided SMEs with essential data, without the requirement for investment in biological safety level 3 infrastructure.

Data generated have helped industrial partners secure Innovate UK funding. The pre-clinical platforms, originally accessed via iiCON, now form the basis of a comprehensive programme to identify, prioritise and validate candidates suitable for phase I and phase II trials.

## EARLY CAREER PROFESSIONAL (ECP) MEET & GREET

4th October 2022, 08.00 - 08.45

5th October 2022, 08.00 - 08.45

Learning Zone

Are you new to ELRIG? Meet with other ECPs who will guide you through all the ECP activities taking place at Drug Discovery 2022 and become part of your network! Free to attend, coffee & pastries will be provided.

## LANGTON HOWARTH - UNDERSTANDING THE NEEDS OF TALENT ACQUISITION DEPARTMENTS TO START A CAREER IN A LIFE-SCIENCE CORPORATIONS: ASK AN EXPERT!

4th October 2022, 10.20 - 10.40

Auditorium 4

- Chris Luche Recruitment Manager, Wellcome Sanger Institute, Wellcome Genome Campus
- Sue Ward, EMEA Talent Acquisition Business Partner – Commercial @ Illumina
- Emma Howarth – MD & Owner, Langton Howarth Ltd - International Life Science & Technology Recruiters

# EARLY CAREER PROFESSIONAL ACTIVITIES

---

## SINGULAR TALENT - GROWING YOUR COMPANY THROUGH GREAT STORY TELLING

4th October 2022, 10.15 - 10.35

Auditorium 4

Speaker: Tom Froggatt, MD, Singular Talent

- How changes in career drivers are making storytelling key to Biotech success
- What stories you should tell
- The impact of great stories on recruitment and retention

## EARLY CAREER PROFESSIONALS: CAREERS IN DRUG DISCOVERY - NETWORK LIKE A BOSS

4th October 2022, 17.15 - 18.15

Auditorium 4

Are you a post-doc, postgraduate, early career researcher or professional (ECP) scientist looking to start or build your career in drug discovery? If so, building and managing your network of contacts is critical to your success. We invite you join us at our ECP speed networking event at ELRIG Drug Discovery 2022. Free to attend and takes place during the Networking hour.

## SCIENCE SOLUTIONS RECRUITMENT - FUTUREPROOF YOUR CAREER IN DRUG DISCOVERY - PANEL DISCUSSION

5th October 2022, 10.20 - 10.55

Auditorium 4

Keynote speakers to provide their perspective on current themes in drug discovery and whether they are “here to stay” or just a fad. Also on how they have “future-proofed” their career so far, mindsets and soft skills acquired and maintained which has kept them agile.

## PANEL DISCUSSION - ENTREPRENEURIAL START UPS 101: CATALYSING INNOVATION IN BIOMEDICAL SCIENCE

5th October 2022, 12.50 - 13.50

Auditorium 4

Chairs: Ms Hanadi Jabado, Prof Aline Miller, Mr Tom Fleming, Dr Michael Salako

Ever wondered what it takes to translate academic findings into small businesses and for spin-outs to grow and be successful? In the last 20 years UK academic institutes have spun out over 1000 companies in drug discovery, biotechnology, diagnostics and therapeutic devices (GovGrants University SpinOut Report 2021). These businesses have attracted £3.6 billion in capital investment, and many such as Exscientia, Orchard Therapeutics and Autolus, have gone on to make significant impacts on healthcare, society and the UK economy. In this panel discussion entrepreneurs, technology transfer experts and early stage investors will discuss the basics of founding, funding and catalysing innovation in biotech start ups, to include:

- What are the essential steps to creating a start -up and what support is out there?
- What are the critical attributes of effective founders & start up teams?
- How to get ideas funded and build value for investors
- Is this the right environment for you to apply your scientific talent?

The panel discussion will be interactive with full audience Q&A, and is open to all ELRIG delegates looking to learn more about early stage biotech businesses, including Early Career Professionals.

## WORKSHOP

### CYTEK BIOSCIENCES WORKSHOP - FULL SPECTRUM PROFILING (FSP)<sup>™</sup>, ADAPTABLE SOLUTIONS TO DEEP IMMUNOPHENOTYPING USING THE CYTEK AURORA: A PRACTICAL WALKTHROUGH


4th October 2022, 12.45 - 13.45

Auditorium 4

Full Spectral profiling (FSP)<sup>™</sup> is often associated with complicated workflows that can be challenging to implement in some research labs. Workflows for the development, optimization of complex immunophenotyping panels for tissue and disease characterization can be time consuming and expensive but are essential to the production of robust data. Here we demonstrate Cytek's® streamlined solutions with FSP<sup>™</sup> to accelerate the movement to high dimensional characterization of immune subsets through simple preoptimized workflows and reagents. This workshop will showcase a live demonstration of Cytek's® comprehensive solutions to facilitate research using our intuitive SpectroFlo® software on a 3 laser Aurora with preoptimized Cytek Assay Settings<sup>™</sup> to acquire our Cytek 14-colour Immunophenotyping Kit. This kit is part of a range of pre-titrated and optimized immunostaining kits with readily downloadable pre-set experimental templates offered by Cytek® as a plug and play solution. We will demonstrate the ease of experimental setup, and the high-quality resolution of immune subsets using Cytek's® offering of expert panel design and cFluor reagents in a single “off the shelf” assay allowing faster access to biological insights.

# FLOOR PLAN

Exhibition - Halls N1 - N3  
Auditoriums - Hall N4



## EXHIBITOR BOOTH LOCATIONS

10x Genomics  
Abcam  
ACROBiosystems  
Agilent Technologies  
AMSBIO  
ApconIX  
Araceli Biosciences  
AstraZeneca Open Innovation

E3/E16  
C3  
B19  
F6  
F1  
A6  
A21  
B14  
AstraZeneca  
Atelerix  
Automata  
Avantor Sciences  
Axol Bioscience Ltd  
Azenta Life Sciences  
AZONetwork  
BD Biosciences

LZ4  
S11  
B1/B2  
R9/R10  
R6  
E4/E5  
S7a  
L12

#ELRIG

#ELRIGDD22

#drugdiscovery

## EXHIBITOR BOOTH LOCATIONS


Beckman Coulter	C1	Hamilton Storage	C13/C14/C17/C18
Benchling	F4	HexagonFab	C2
Bio Molecular Systems Ltd	B22	HORIBA	E12
Bio-Rad	D3/D10	HUB Organoids	E17
Bio-Techne	S10	IBI Journal	A17b
BioAscent	A2	IDBS	E2
Biocair	F11	Iktos	C29
BiolVT	A20	Innoprot	F13
Biorelate	E10	Integra Biosciences	B6/B13
BioSero	S12	IotaSciences	B16
BioStrata	A3	Lablogic Systems	A8/A15
Bit Bio	E6/E13	Langton Howarth	LZ9
BlueCatBio	C12	LGC - ATCC	C28
BMG LABTECH	C19/20	LifeArc	LZ2
British Pharmacological Society	A17a	MDS	LZ8
Bruker	S8	MedChemExpress	C21
Caltag Medsystems	E1	Medicilon	A5b
Cambridge Bioscience	D1	Medicines Discovery Catapult	D9
Cancer Research Horizons	B20	Miltenyi	C6/C7
Carterra	A4	MolGen	C15/C16
CBRE Integrated Laboratory Solutions	B15	Ncardia	C22
Cell Signaling Technology	L9	Newcells Biotech	L11
Cellbox Solutions	D12	Nexcelom from PerkinElmer	D7/D8
Cellenion	A19	Organoid Spheroid	A12
CELLINK	R3/R4/R5	Oxford Nanopore Technologies	B5
Charnwood Molecular	C26/C27	Peak Proteins	C24
CN-Bio	B23	Pelago Bioscience	D4
Collaborative Drug Discovery	C4	PeproTech	S7
Core Life Analytics	R11	Pharmaron	F12
Corning Life Sciences	A16	Promega	B4
Creoptix	F9	Proteintech	E15
Cryoniss	C23	Proteome Sciences Plc	B3
Cytek Biosciences	R10a	Royal Society of Chemistry	LZ7
CYTENA	R3/R4/R5	RSK-Solutions	A11
Dispendix	R3/R4/R5	Scientific Solutions Recruitment	LZ1
DIVERSA Technologies	F15	Sengenics	E11
Drug Target Review	E14	Singular Talent	LZ3
ECP Meet & Greet	LZ5	Standard Bio	L10
EDIS	F8	Stemcell	L11a
Elemental Machines	A5	Stratech Scientific	E9
Eurofins Discovery	C10	SUN Bioscience	D2
FESTO	C25	Synthego	D5 & D6
Fida Biosystems	C30	Takara Bio Europe	R7
Fios Genomics	B17	TargetMol	D11
Flexible Lab Solutions	F5	Tecan	B7/B6/B11/B12
Flow Robotics	A7	The European Collection of Authenticated	C11
Formulatrix	C8/C9	Cell Cultures	
Fortis Life Sciences	F2/F3	Thermo Fisher Scientific	F10
Fritz Gyger AG	E7	Twist Bioscience	B9/B10
Fusion Antibodies	E18	UPM	E8
Genedata	R1/R2	Veon Scientific	S9
Gilson	F14	WuXi AppTec	C5
Greiner Bio One	L7/L8	Yokogawa Deutschland	F7
GlaxoSmithKline	LZ6	Ziath	B18
Hamilton	C13/C14/C17/C18	Zyme	LZ10





# PROGRAMME AT A GLANCE


DAY 1	AUDITORIUM 1	AUDITORIUM 2	AUDITORIUM 3	AUDITORIUM 4	ELRIG TECH THEATRE SUPPORTED BY DDW
08.00-09.10	Registration at entrance of Exhibition Hall Early Career Professional Meet & Greet in the Learning Zone				
09.10-10.20	Conference Welcome, ELRIG Yearly Report & Keynote Presentation				
10.20-11.05	Refreshment Break			Early Career Professional Skills Training Workshop	Automation in Drug Discovery Seminar
11.05-12.45	High Content Imaging in Drug Discovery	Overcoming Challenges and New Directions in Medicinal Chemistry	Cell & Gene Therapy Sponsored by Miltenyi	Drug Discovery and Development in COPD. A track organised by the BPS	
12.45-14.00	Refreshment break Sponsored by CRL, with poster session, in the Exhibition Hall			Cytek Biosciences Workshop	Automation in Drug Discovery Seminar
14.00-15.10	High Content Imaging in Drug Discovery	Overcoming Challenges and New Directions in Medicinal Chemistry	Cell & Gene Therapy Sponsored by Miltenyi	Drug Discovery and Development in COPD. A track organised by the BPS	Sales & Marketing Skills Workshop – For Exhibitors Only
15.10-15.45	Refreshment Break			Early Career Professional Skills Training Workshop	Automation in Drug Discovery Seminar
15.45-17.00	High Content Imaging in Drug Discovery	Overcoming Challenges and New Directions in Medicinal Chemistry	Cell & Gene Therapy Sponsored by Miltenyi	Drug Discovery and Development in COPD. A track organised by the BPS	
17.00-19.00	Networking, Sponsored by CRL, with poster session in Exhibition Hall Early Career Professional - Network like a boss in the Exhibition Hall				
19.00 to late	ELRIG's Celebration of Drug Discovery, sponsored by Synthego, at The Fox, ExCel				

Exhibition Hall open from 08.00 to 19.00

 Scientific Conference Talks

 Automation in Drug Discovery

 Early Career Professional Activities

 Talks for Exhibitors

#ELRIG

#ELRIGDD22

#drugdiscovery



# PROGRAMME AT A GLANCE

DAY 2	AUDITORIUM 1	AUDITORIUM 2	AUDITORIUM 3	AUDITORIUM 4	ELRIG TECH THEATRE SUPPORTED BY DDW
08.00-09.00	Registration at entrance of Exhibition Hall Early Career Professional Meet & Greet in the Learning Zone				
09.00-10.20	Conference Welcome, Early Career Professional Impact Award, Poster Prize Winners Presentation & Keynote Presentation				
10.20-11.00	Refreshment Break			Early Career Professional Skills Training Workshop	Automation in Drug Discovery Seminar
11.00-12.50	Developments in Preclinical Models	Innovation through Partnership sponsored by AstraZeneca Open Innovation	Advancements in Screening and Automation. A track organised by SLAS and sponsored by IDBS	Frontiers of Chemistry applied to Drug Discovery. A track organised by the RSC	Exhibitor 360 Forum - Exhibitors Only
12.50-14.00	Refreshment break Sponsored by CRL, with poster session, in the Exhibition Hall			Early Career Professional Skills Training Workshop	Automation in Drug Discovery Seminar
14.00-15.10	Developments in Preclinical Models	Innovation through Partnership sponsored by AstraZeneca Open Innovation	Advancements in Screening and Automation. A track organised by SLAS and sponsored by IDBS	Frontiers of Chemistry applied to Drug Discovery. A track organised by the RSC	
15.10-15.45	Refreshment Break				Automation in Drug Discovery Seminar
15.45-16.45	Developments in Preclinical Models	Innovation through Partnership sponsored by AstraZeneca Open Innovation	Advancements in Screening and Automation. A track organised by SLAS and sponsored by IDBS	Frontiers of Chemistry applied to Drug Discovery. A track organised by the RSC	

Exhibition Hall open from 08.00 to 15.45

SiLA Hackathon taking place on Monday 3rd October in the Exhibition Hall

	Scientific Conference Talks		Early Career Professional Activities
	Automation in Drug Discovery		Talks for Exhibitors

# ELRIG'S TECH THEATRE PROGRAMME

## SUPPORTED BY DDW

---

### DDW - FIRST STEPS INTO AUTOMATION: THE CHALLENGES – FINANCIAL, SKILLS, OBJECTIONS - AND HOW TO OVERCOME THEM

4th October 2022

10.20

How to make the initial move into automation. Sometimes a benchtop system is enough to help achieve productivity gains. How do you define your needs, the financial payback you require and how do you redeploy lab expertise to further benefit from new technology? How can labs take small steps and why simple automation and data sharing, can be as powerful as large steps.



### DDW - THE ROLE OF AI AND AUTOMATION IN PERSONALISED MEDICINE: HOW CAN AI HELP IN THE POST DRUG DISCOVERY PROCESS

4th October 2022

12.45

- How can automation and AI be used to expedite the drug discovery process?
- What benefits can these technologies create?
- What are the barriers for entry and might prevent better uptake?
- What are the challenges of using this technology and how can they be surmounted?
- What role does technology have in the post drug discovery process?

#### SPEAKER

Dr Yahya Anvar  
OKRA.ai

### DDW - DATA HANDLING AND CHOOSING THE RIGHT INFORMATICS SYSTEMS FOR YOUR LAB REQUIREMENTS

4th October 2022

13.20

Making improvements to digitisation is a two-stage problem, we need to encourage people to digitise more, and we need better systems to manage the plethora of electronic data once it makes its way into digital form. This presentation will consider both of these aspects by discussing the current state of digitisation of scientific research, including how things have changed (or not) since COVID-19, the barriers (and suggested mitigations) to these barriers, and the digitisation requirements of the physical sciences community.



#### SPEAKER

Samantha Kanza  
University of Southampton

### DDW - HOW CAN AUTOMATION HELP THE DISCOVERY OF BIOLOGICS AND BIOSIMILARS?

4th October 2022

15.15

- The challenges of biologic discovery and ways that automation can benefit the process
- What type of technology can help drive efficiency into the process and create optimal drug discovery?
- What are the challenges within this process and how can they be overcome?



#### SPEAKER

Zoe Hughes-Thomas  
GlaxoSmithKline

# ELRIG'S TECH THEATRE PROGRAMME

## SUPPORTED BY DDW

---

### DDW - THE LAB OF THE FUTURE IS NOW: USING AI OR AUTOMATION FOR THE DISCOVERY PROCESS

5th October 2022  
10.20

In this talk, Nicola Richmond, VP of AI, will give an overview of BenevolentAI's unique AI-augmented, hypothesis-driven drug discovery platform and how its application is capable of generating novel targets at scale.



**SPEAKER**  
**Nicola Richmond**  
BenevolentAI

### DDW - THE SUSTAINABLE LAB. BUILDING A GLOBAL CULTURE OF SUSTAINABILITY IN SCIENCE

5th October 2022  
12.50

This talk will address the global growth of the green lab movement, My Green Lab's vision for the industry and alignment with the UN race to zero campaign. It will cover My Green Lab's *Carbon Impact of the Biotech & Pharma* study and how programs are being utilised by labs in sectors including academia, pharma, biotech and wider, to run labs in a more sustainable way and green their supply chains.

**SPEAKER**  
**Raj Patey**  
My Green Lab

### DDW - THE AUTOMATED LAB AND THE HUMAN

5th October 2022  
13.30

During this session Prosho will be using his career to-date as an example of the varied roles the human plays in the Automated Lab. He will outline how these roles have changed over the years due to a combination of generational shifts across the workforce, advances in the field of lab automation and the explosion of data analytics and machine learning. He will also cover how employers, manufacturers and CBRE are adapting their offerings to meet this 21st century workplace.



**SPEAKER**  
**Adam Prosho**  
CBRE

### DDW - THE REMOTE LAB: IS THIS THE FUTURE?

5th October 2022  
15.15

- Is the lab of the future remote?
- What benefits will this create for drug discovery and development researchers?
- What savings can it create?
- Will virtual working become the new norm or is a likely scenario a physical and virtual hybrid?
- How are technology suppliers addressing the virtual lab and what can they offer the research sector that improves current working practices?

**SPEAKER**  
**Zoe Hughes-Thomas**  
GlaxoSmithKline

# TRACK SUMMARY

## HIGH CONTENT IMAGING IN DRUG DISCOVERY

4th October 2022  
Auditorium 1

High content imaging (HCI) is now a familiar and in many cases, a routine approach for investigating and analysing the multiparametric events occurring within cells and is used as a standard tool in many academic and Pharma environments. HCI is increasingly being deployed in more technologically challenging environments such as organoid and 3D model systems as well as drawing on machine learning & AI

### SESSION CHAIRS

Sian Lewis  
MSD  
Michael Howell  
The Francis Crick Institute

advances to drive drug discovery efforts. With this session we assess the current standing of HCI in drug discovery by taking a snapshot of current and near-future activities in this arena; has the early promise of HCI been fully realised? Do we get the most benefit from our hard won HCI data? Is there such a thing as too much data? Is there an emerging consensus as to the best way to deploy HCI in DD.

08.00-09.10	Registration
09.10-09.30	ELRIG Annual Review
09.30-09.35	Conference Welcome & Keynote Introduction
09.35-10.20	Plenary Keynote - <b>New technologies for the design and characterisation of nanotechnology mediated therapeutics</b> - Molly Stevens, Imperial College London
10.20-11.05	Refreshment Break
11.05-11.10	Session Chair Introduction - Sian Lewis, MSD & Michael Howell, The Francis Crick Institute
11.10-11.40	<b>High Content Imaging as an enabling tool for early drug discovery</b> - John Bassett, MSD
11.40-12.10	Platinum Presentation - <b>Patient-Derived Cell (PDC) Models as a Tool to Assess Cancer Therapeutic Efficacy Across the Drug Development Life Cycle</b> - Rachel Howard-Jones, Imagen Therapeutics on behalf of Nexcelom
12.10-12.40	<b>Accelerating Drug Discovery with Cell Painting</b> - James Pilling, AstraZeneca
12.40-12.45	Bronze Sponsorship - <b>Microplate readers and imaging systems</b> - Imran Haneef, Lablogic
12.45-14.00	Refreshment Break, Sponsored by CRL, with Poster Session 13.15-13.45
14.00-14.30	<b>Phenonaut; a tool for multiomic data integration, analysis, prediction, and inference</b> - Steve Shave, University of Edinburgh & GSK
14.30-14.35	Bronze Sponsorship - <b>10x Your Lab: High Content Analysis Meets High-Throughput Screening</b> - Kristin Halfpenny, Araceli Biosciences
14.35-14.40	Bronze Sponsorship - <b>spheroONE – an automated high throughput spheroid isolation and manipulation technology</b> - Alice Cheesbrough, Cellenion
14.40-15.10	<b>Life beyond the pixels: single-cell analysis using deep learning and image analysis methods</b> - Peter Horvath, Biological Research Centre, Szeged
15.10-15.45	Refreshment Break
15.45-16.15	<b>Morphological trajectory inference: Tracking cell state transitions and the impact of small-molecule perturbations</b> - Rebecca Hughes, University of Edinburgh
16.15-16.30	Industry Insider Sponsorship - Gary Allenby, Charnwood Molecular & Katy Dodgson, Charnwood Molecular
16.30-17.00	<b>Quantitative high-throughput screening of single cancer cell phenotypes in 3D matrices</b> - Vicky Bousgouni, ICR
17.00-19.00	Networking, Sponsored by CRL, in The Exhibition Hall with Poster Session 18.30-19.00

 Presenters will appear in-person, unless marked with this icon, when they appear virtually.

# TRACK SUMMARY

## OVERCOMING CHALLENGES AND NEW DIRECTIONS IN MEDICINAL CHEMISTRY

4th October 2022  
Auditorium 2

### SESSION CHAIRS

Allan Jordan  
Sygnature Discovery  
Sarah Skerrat  
CHARM Therapeutics

Even relatively recently, many key proteins and processes in human disease have been considered “undruggable”. However, recent advances against targets such as the RNA spliceosome and KRAS G12C have started to re-define the concept of druggability and how we can deliver forefront medicines across a range of diseases. In this session, we will celebrate some of the recent

advances in this space, describing the impact of synthetic and medicinal chemistry in delivering agents against challenging diseases. Importantly, the talks will share key lessons learnt, to assist future success against equally challenging targets and our panel of experienced medicinal chemists will discuss their own experiences, future directions and upcoming challenges.

08.00-09.10	Registration
09.10-10.20	All Presentations in Auditorium 1
10.20-11.05	Refreshment Break
11.05-11.10	Session Chair Introduction - Allan Jordan, Sygnature Discovery & Sarah Skerrat, CHARM Therapeutics
11.10-11.40	<b>Discovery and validation of in vitro and in vivo probes for human DNA Polymerase theta (Polθ)</b> - Rob Heald, Artios Pharma
11.40-12.10	<b>The COVID Moonshot – from open science collaboration in fragment screening to drug candidate and beyond to Pandemic Preparedness</b> - Ed Griffen, MedChemica Ltd
12.10-12.40	<b>ML/AI: Opportunities, Impact and Future Directions in Drug Design</b> - Sarah Skerrat, CHARM Therapeutics
12.40-12.45	Bronze Sponsorship
12.45-14.00	Refreshment Break, Sponsored by CRL, with Poster Session 13.15-13.45
14.00-14.30	<b>Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery - Design tips and tricks</b> - Jamie Scott, AstraZeneca
14.30-14.35	Bronze Sponsorship - <b>Supporting innovations in Spliceosome research</b> - Roslyn McConnell, Avantor
14.35-14.40	Bronze Sponsorship
14.40-15.10	<b>New Approaches to the Synthesis and Application of DNA-Encoded Libraries</b> - Jessica Graham, Newcastle University & Harriet Stanway-Gordon, Newcastle University
15.10-15.45	Refreshment Break
15.45-16.15	<b>Targeting the template: A novel therapeutic strategy for prion diseases</b> - Heulyn Jones, Cardiff University
16.15-16.30	Industry Insider Sponsorship - <b>Navigate Your Chemistry And Explore The Biology - Case Studies Of CETSA® overcoming challenges in Drug Discovery</b> - Isabel Martin Caballero, Pelago
16.30-17.00	Audience Lead Panel Discussion with Q&A
17.00-19.00	Networking, Sponsored by CRL, in The Exhibition Hall with Poster Session 18.30-19.00

 Presenters will appear in-person, unless marked with this icon, when they appear virtually.

# TRACK SUMMARY

SPONSORED BY

## CELL & GENE THERAPY SPONSORED BY MILTENYI



4th October 2022  
Auditorium 3

### SESSION CHAIRS

Chris Herring  
Adaptimmune  
Claire Dobson  
AstraZeneca

Often grouped together, these two complementary disciplines of therapy have not only delivered clinical impact through the efforts of academics and biotechs, they have also become pillars of many pharmaceutical companies medicine pipelines. With approaches as diverse as in vivo expressed biologics, CRISPR-based therapeutic gene editing and allogeneic immune cell

engineering, it is easy to overlook the commonalities between this wide range of medicine formats. This session will provide an update on advances in this increasingly mainstream area of drug discovery, as well as shine a light on some of the shared challenges academics, clinicians and industry scientists are working together to overcome.

08.00-09.10	Registration
09.10-10.20	All Presentations in Auditorium 1
10.20-11.05	Refreshment Break
11.05-11.10	Session Chair Introduction - Chris Herring, Adaptimmune & Claire Dobson, AstraZeneca
11.10-11.40	<b>TCR Evolution, revolution: How Adaptimmune is developing innovative TCR T-cell therapies to treat solid tumors</b> - Jo Brewer, Adaptimmune
11.40-12.10	Platinum Presentation - <b>The journey from discovery to therapy begins with a single cell</b> - Stephen Hague, 10 x Genomics
12.10-12.40	<b>From Stem-Cells to T-Cells: Next-Generation DNA NanoVectors -an Alternative Non-Integrating DNA Vector Platform for Regenerative Medicine and Immunotherapy</b> - Richard Harbottle , German Cancer Research Centre (DKFZ)
12.40-12.45	Bronze Sponsorship - <b>Automating high-throughput NGS and qPCR assays: Meet the Biomark™ X and the Juno™</b> - James Curtis, Standard Bio Tools
12.45-14.00	Refreshment Break, Sponsored by CRL, with Poster Session 13.15-13.45
14.00-14.30	<b>Pin-point™ – A Modular Base Editing System Driving Cell and Gene therapies</b> - Michael Anbar, Horizon
14.30-14.35	Bronze Sponsorship - <b>Assist Plus Pipetting Platform</b> - Sharon Barnard, Integra Biosciences Ltd
14.35-14.40	Bronze Sponsorship - <b>Bioluminescent assay tools for TCR-T and CAR-T development and characterisation</b> - Craig Malcolm, Promega
14.40-15.10	<b>Armouring CAR-T cells therapy against the immunosuppressive microenvironment in solid tumour</b> - Romain Lara, AstraZeneca
15.10-15.45	Refreshment Break
15.45-16.15	<b>Unlocking a revolutionary class of in vivo reprogramming therapies through systematic, unbiased identification of the key cell switches controlling cell fate</b> - Louise Modis, Mogrify
16.15-16.30	Industry Insider Sponsorship - <b>The impact of not understanding the genetic landscape, Ignorance will cost you time and money</b> - Melanie Maerken, Synthego
16.30-17.00	<b>Next Generation Platforms for Human Gene Therapy</b> - Aravind Asokan, StrideBio/Duke University 
17.00-19.00	Networking, Sponsored by CRL, in The Exhibition Hall with Poster Session 18.30-19.00

 Presenters will appear in-person, unless marked with this icon, when they appear virtually.



# TRACK SUMMARY

## DRUG DISCOVERY AND DEVELOPMENT IN COPD (BPS)

4th October 2022  
Auditorium 4



COPD remains a major medical challenge resulting from smoking and increasingly due to oxidant airborne pollutants. COPD is suggested to become the third leading cause of death globally by 2030 and currently affects approximately 17.4 million people. Furthermore, there is now a growing recognition that COPD is a syndrome with both changes in the respiratory system and systemic co-morbidities, particularly in the cardiovascular systems, and even depression. Current therapy is largely administered by inhalation to treat the respiratory symptoms, with drugs mainly developed

### SESSION CHAIRS

**Simon Pitchford**

King's College London

**Anna Morgan**

Physiology & Pharmacology, Kingston University

not to enter the systemic circulation to avoid unwanted effects. However, in the future we need to consider systemic treatments to also address these important co-morbidities. This track will review the current "state of play" of our understanding of the pathogenesis of COPD and the current limitations of current treatment approaches. The track will discuss assays to identify novel molecular targets to help find new drugs for the treatment of COPD and the "Therapeutic Innovation" currently in the pipeline.

08.00-09.10	Registration
09.10-10.20	All Presentations in Auditorium 1
10.20-11.05	Refreshment Break
11.05-11.10	Session Chair Introduction - Simon Pitchford, King's College London & Anna Morgan, Physiology & Pharmacology, Kingston University
11.10-11.40	<b>The burden of unmet needs in COPD</b> - Wisia Wedzicha, National Heart and Lung Institute, Imperial College London
11.40-12.10	<b>Novel drug targets in COPD</b> - Ian Adcock, National Heart and Lung Institute, Imperial College London
12.10-12.15	Bronze Sponsorship - <b>New perspectives for modelling inflammatory diseases using patient-derived organoids</b> - Sylvia F. Boj, Hubrecht Organoid Technology
12.15-12.45	<b>Use of Imaging for preclinical evaluation of drugs for the treatment of COPD</b> - Anna Morgan, Kingston University
12.45-14.00	Refreshment Break, Sponsored by CRL, with Poster Session 13.15-13.45
14.00-14.30	<b>Preclinical translational models for investigating drugs for the treatment of COPD</b> - Simon Pitchford, King's College London
14.30-14.35	Bronze Sponsorship
14.35-14.40	Bronze Sponsorship
14.40-15.10	<b>Use of human tissues to investigate drugs for the treatment of COPD</b> - Luigi Calzetta, Universita' of Parma
15.10-15.45	Refreshment Break
15.45-16.15	<b>Early experimental medicine studies for investigating new drugs for COPD</b> - Dave Singh, University of Manchester
16.15-16.30	Industry Insider Sponsorship - <b>Methods to tackle novel molecular targets involved in inflammatory disease</b> - Mark Abbott, Peak Proteins
16.30-17.00	<b>Publishing in the British Journal of Pharmacology</b> - Charles Whalley, British Pharmacology Society
17.00-19.00	Networking, Sponsored by CRL, in The Exhibition Hall with Poster Session 18.30-19.00

Presenters will appear in-person, unless marked with this icon, when they appear virtually.

# TRACK SUMMARY

## DEVELOPMENTS IN PRECLINICAL MODELS

5th October 2022  
Auditorium 1

### SESSION CHAIRS

Lisa Mohamet  
GlaxosmithKline  
Sam Barichiev  
AstraZeneca

Driven by increased disease insight as well as a renaissance in screening approaches such as Functional Genomics, understanding biology, as well as the behaviour of emerging drug targets and candidate medicines within a complex cellular environment is critical to modern research. Academics and industry scientists

are increasingly turning to advanced preclinical models in order to identify and validate new biological hypotheses, as well as mitigate the risks of clinical efficacy- and safety-based attrition for new medicines. This session will highlight some of the most exciting preclinical model systems at the forefront of this wave of innovation”.

08.00-09.00	Registration
09.00-09.05	Conference Welcome & Keynote Introduction
09.05-09.50	Plenary Keynote - <b>Genomic Sciences in Immunology – Strategies for Finding Future Drug Targets through Genetics, Functional Genomics and Immunophenotyping</b> - Rab Prinjha, GlaxoSmithKline
09.50-09.55	ECP Impact Award Introduction - Mark Soave & Elemental Machines
09.55-10.15	ELRIG Early Career Professional Impact Award - <b>Pandemic response: accessible BSL3 platforms for drug discovery</b> - Shaun Pennington, LSTM
10.15-10.20	Poster Prize Awards
10.20-11.00	Refreshment Break
11.00-11.05	Session Chair Introduction - Lisa Mohamet, GlaxosmithKline & Sam Barichiev, AstraZeneca
11.05-11.35	<b>Biomarker Discovery Using Preclinical Models: Resources, Challenges and Opportunities</b> - Benjamin Haibe-Kains, University of Toronto
11.35-12.05	Platinum Presentation - <b>Developments in Cytometry Technology to Enhance Pre-Clinical Workflows: StarBright Dyes and the ZE5 Cell Analyzer</b> - Richard Cuthbert, Bio-Rad AbD Serotec Ltd
12.05-12.35	<b>Utilising complex in vitro gut models in drug discovery: they needn't be hard to stomach</b> - Nathaniel Lam, GSK, UK
12.35-12.50	Industry Insider Sponsorship - <b>Using human iPSC technology to model disease-relevant signatures of Alzheimer's disease and other tauopathies</b> - Laura Calo, NCARDIA
12.50-14.00	Refreshment Break, Sponsored by CRL, with Poster Session 13.15-13.45
14.00-14.30	<b>Organoid Biobanks for Cancer Drug Discovery</b> - Matthew Garnett, Sanger Institute
14.30-14.35	Bronze Sponsorship - <b>New/Novel/Ground-breaking technologies assisting the sustainable preclinical drug discovery</b> - Karthi Rajamani, Takara Bio Europe
14.35-14.40	Bronze Sponsorship - <b>From HTS Campaign to Biophysical Characterization: The Art of Generating Promising Hit Series for PIM3 Kinase</b> - Celine Legros, Eurofins
14.40-15.10	<b>Upgrading African disease-in-a-dish models for pharmacovigilance: Enter the humble cell</b> - Janine Scholefield, CSIR, South Africa
15.10-15.45	Refreshment Break
15.45-16.15	<b>Generating improved preclinical models for profiling novel combinations</b> - Elizabeth Hardaker, AstraZeneca, UK
16.15-16.45	<b>Image-based drug screening in patient biopsies for personalized systems medicine and drug discovery</b> - Berend Snijder, ETH

 Presenters will appear in-person, unless marked with this icon, when they appear virtually.

## INNOVATION THROUGH PARTNERSHIP SPONSORED BY ASTRAZENECA OPEN INNOVATION

5th October 2022  
Auditorium 2



### SESSION CHAIRS

**Kathryn Chapman**  
Milner Therapeutics Institute  
**Dave Powell**  
LifeArc

The landmark collaboration between Oxford University and AstraZeneca for the further development, large-scale manufacture and distribution of the COVID-19 vaccine candidate has demonstrated, globally, the power of partnership to deliver on medicines and to

solve challenging unmet needs. ELRIG have created this session to celebrate the thriving Bioscience network of research and commercial partnerships and to highlight and discuss approaches for funding your ideas.

08.00-09.00	Registration
09.00-10.20	All Presentations in Auditorium 1
10.20-11.00	Refreshment Break
11.00-11.05	Session Chair Introduction - Kathryn Chapman, Milner Therapeutics Institute & Dave Powell, LifeArc
11.05-11.35	<b>KQ Labs accelerator for data driven health start-ups: why does it exist, what does it do and what difference does it make?</b> - Barbara Domayne-Hayman, The Francis Crick Institute & Jelena Aleksic, PharmEnable
11.35-12.05	Platinum Presentation - <b>Developing strategic partnerships to accelerate worldwide access to human cells</b> - Kam Dhaliwal, BitBio & David Fischer, CRL
12.05-12.35	<b>The Joint AstraZeneca-Cancer Research Horizon Functional Genomics Centre (FGC): A partnership demonstrating how together we innovate faster and impact more</b> - Doug Ross-Thriepeland, AstraZeneca
12.35-12.50	Industry Insider Sponsorship - <b>Beyond Small Molecules...</b> - Dave Madge, WuXi
12.50-14.00	Refreshment Break, Sponsored by CRL, with Poster Session 13.15-13.45
14.00-14.30	<b>The Drug Discovery Unit: Leading the development of new anti-infective treatments with a collaborative approach</b> - Beatriz Baragana, University of Dundee
14.30-14.35	Bronze Sponsorship - <b>Pressure over liquid – Established technology but with new value</b> - Paul Kendal, Festo SE & Co KG
14.35-14.40	Bronze Sponsorship - <b>Building a Strong Digital Foundation to Accelerate Innovation and Drug Discovery</b> - Oliver Pentinmaki, Benchling
14.40-15.10	<b>Dementia Drugs through Partnership at the ALBORADA Drug Discovery Institute</b> - John Skidmore, University of Cambridge
15.10-15.45	Refreshment Break
15.45-16.15	<b>The benefits of working side-by-side: The Crick-GSK Biomedical LinkLabs collaboration</b> - Andrew Powell, GlaxoSmithKline & Katrin Rittinger, The Francis Crick Institute
16.15-16.45	<b>Advancing UK Medicines Discovery through Innovative Partnerships</b> - Martin Main, Medicines Discovery Catapult

Presenters will appear in-person, unless marked with this icon, when they appear virtually.

## ADVANCEMENTS IN SCREENING AND AUTOMATION (SLAS) SPONSORED BY IDBS



5th October 2022  
Auditorium 3



### SESSION CHAIRS

**Mario Richter**  
AbbVie Deutschland GmbH & Co. KG  
**Kirsten Tschapalda**  
Roche

In the ELRIG-SLAS joint session novel approaches to laboratory automation and screening will be shared. What does a lab of the future look like and how to get there? The speakers will give us an insight into their ideas,

solutions, new technologies and share their experience. Making screening tools and automation more universal and easy to implement is and will be an important topic in the years to come.

08.00-09.00	Registration
09.00-10.20	All Presentations in Auditorium 1
10.20-11.00	Refreshment Break
11.00-11.05	Session Chair Introduction - Mario Richter, AbbVie Deutschland GmbH & Co. KG & Kirsten Tschapalda, Roche
11.05-11.35	<b>Efficient low-priced custom automation at Abbvie</b> - Mario Richter, AbbVie Deutschland GmbH & Co. KG
11.35-12.05	Platinum Presentation - <b>Automated analysis workflow to identify metal contamination in HTS outputs</b> - Rachel Moore, Genedata AG
12.05-12.35	<b>iPSC automation platform</b> - Martine Geraerts, UCB
12.35-12.50	Industry Insider Sponsorship - <b>Multiparametric drug discovery facilitated by acoustic liquid handling</b> - Mark Graham, Beckman
12.50-14.00	Refreshment Break, Sponsored by CRL, with Poster Session 13.15-13.45
14.00-14.30	<b>Collaborative AMR Implementation in Biopharmaceutical Labs</b> - Thomas Albanetti, AstraZeneca 
14.30-14.35	Bronze Sponsorship - <b>HTS Assay detection at its best! - New PHERAstar FSX features improve data quality and sample processing</b> - Catherine Wark, BMG Labtech
14.35-14.40	Bronze Sponsorship - <b>Cost Effective Decapping</b> - Adam McGinnis, Azenta Life Sciences
14.40-15.10	<b>An Educational Approach for Drug Discover Using AI Driven Closed Loop Experimentation</b> - Joshua Kangas, Carnegie Mellon University, PA 
15.10-15.45	Refreshment Break
15.45-16.15	<b>Enhancing the lead discovery assay value chain by an orchestrated lab automation ecosystem</b> - Kirsten Tschapalda, Roche & Federica Morandi, Roche
16.15-16.45	<b>High Throughput Affinity Screening for Rapid Hit Discovery and Prosecuting Challenging Targets</b> - Poppy Llowarch, AstraZeneca

 Presenters will appear in-person, unless marked with this icon, when they appear virtually.

# TRACK SUMMARY

## FRONTIERS OF CHEMISTRY APPLIED TO DRUG DISCOVERY – (RSC)

5th October 2022  
Auditorium 4



Sustainability, innovation, new modalities, synthetic methodology, target validation; what impact do all of these have on drug discovery and how can we use the most recent advances to improve the medicines we make? In this track we will hear about recent advances in sustainable chemistry, new synthetic methodology and its impact on drug discovery. We explore the interface between chemistry and biology, and how we are pushing the boundaries of drug discovery today. This session is hosted by the Biological and Medicinal Chemistry Sector

### SESSION CHAIRS

**A. Ganesan**  
University Of East Anglia  
**Mary Wheldon**  
University of Dundee  
**Martin Swarbrick**  
Ryvu Therapeutics

**Becky Garton**  
Royal Society of Chemistry  
**Katie Lim**  
Royal Society of Chemistry

(BMCS) and RSC Medicinal Chemistry. The BMCS is a member-driven interest group of the Royal Society of Chemistry (RSC) which aims to further the interests of all members of the RSC, both industrial and academic, involved in the pursuit and understanding of biologically active molecules. A journal published on a not-for-profit basis by the RSC, RSC Medicinal Chemistry publishes significant research and new thinking in medicinal chemistry and drug discovery science.

08.00-09.00	Registration
09.00-10.20	All Presentations in Auditorium 1
10.20-11.00	Refreshment Break
11.00-11.05	Session Chair Introduction - A. Ganesan, University Of East Anglia, Mary Wheldon, University of Dundee, Martin Swarbrick, Ryvu Therapeutics, Becky Garton, Royal Society of Chemistry & Katie Lim, Royal Society of Chemistry
11.05-11.35	<b>Platforms for the generation and high-throughput screening of cyclic peptide libraries</b> - Ali Tavassoli, University of Southampton and Curve Therapeutics
11.35-12.05	<b>Green Chemistry at GSK - How and when to use guides, and using Green Chemistry to design a scalable route to a first-in-class BET BD2 inhibitor</b> - Catherine Alder, GlaxoSmithKline
12.05-12.35	<b>Ligand discovery in dark chemical space leading to biological insights</b> - John Irwin, University of California
12.35-12.50	<b>Industry Insider Sponsorship - Oxford Nanopore Technologies - a look into the complete genome</b> - Daniel Fordham, Oxford Nanopore Technologies
12.50-14.00	Refreshment Break, Sponsored by CRL, with Poster Session 13.15-13.45
14.00-14.30	<b>Discovery of the clinical candidate, ASTX029, a dual mechanism ERK inhibitor</b> - Nicola Wallis, Astex
14.30-14.35	<b>Bronze Sponsorship - Flow Induced Dispersion Analysis (FIDA) Protein QC: Linking absolute hydrodynamic radius determination to structural insight</b> - Joanne Walter, Fidabio
14.35-14.40	<b>Bronze Sponsorship - TargetMol: Targets small molecules in drug discovery</b> - Phoebe Feng, TargetMol
14.40-15.10	<b>The Discovery and Clinical Efficacy of Sisunatovir</b> - Stuart Cockerill, Pfizer
15.10-15.45	Refreshment Break
15.45-16.15	<b>Discovery and Development of Pyrukynd®: The First-in-Class Pyruvate Kinase Activator For The Treatment of Hemolytic Anemia</b> - Lenny Dang, Agios
16.15-17.00	<b>Simplifying Synthesis with Electricity</b> - Phil Baran, Scripps Institute 

 Presenters will appear in-person, unless marked with this icon, when they appear virtually.

# ELRIG EVENTS 2023

## KEY EVENTS

ELRIG is a learned society that organises scientific conferences and forums, for the European drug discovery community. Meetings will have anywhere between 40 to 1500 attendees. Meetings may be an afternoon only to 2 days in length and have a very narrow focus or contain a broad range of topics, applicable to many research areas within the drug discovery community. All events are free-to-attend, simply register at [elrig.org](https://elrig.org). Remaining events for 2022 and future events for 2023 are:



## REMAINING EVENTS IN 2022

### PROTEIN SCIENCES IN DRUG DISCOVERY 2022

Astra Zeneca, Cambridge  
November 2nd - 3rd

### ROBOTICS & AUTOMATION 2022

Festo, Esslingen, Stuttgart  
November 30th - December 1st

## EVENTS IN 2023

### 2023 CONFERENCES

#### CRISPR IN DRUG DISCOVERY 2023

The Kings Centre, Oxford  
February 7th - 8th

#### RESEARCH & INNOVATION 2023: ACCELERATING FUTURE DRUG DISCOVERY

Hinxton, Cambridge  
March 29th - 30th

#### THE ELRIG THERAPEUTIC OLIGO AND THE EUROPEAN CHEMICAL BIOLOGY CONFERENCE 2023

AstraZeneca, Gothenburg  
May 9th - 11th

#### DRUG DISCOVERY 2023

ACC Liverpool  
October 18th - 19th

#### HIGH CONTENT IMAGING AND FLOW CYTOMETRY IN DRUG DISCOVERY 2023

GSK, Stevenage  
November 21st - 22nd

### 2023 FORUMS

#### LABEL-FREE MASS SPECTROMETRY ASSAYS FOR EARLY DRUG DISCOVERY

The Netherlands  
January 25th

#### SUSTAINABILITY PRACTICES IN DRUG DISCOVERY RESEARCH

Oxford  
April 19th

#### THE SCOTTISH RESEARCH AND DRUG DEVELOPMENT FORUM

Scotland  
April 27th

#### DISCOVERY TECHNOLOGIES 2023: COMPLEX MEDICINES FORUM

Alderley Park  
June 22nd

#### ADVANCEMENTS IN CELL & GENE THERAPY: NEW THERAPEUTIC HORIZONS

Basel  
September 21st

#### FRENCH DRUG DISCOVERY FORUM

France  
December 6th

### 2023 NETWORKING EVENTS

#### CAMBRIDGE

May 23rd

#### LONDON

June 29th

All events are in-person and free of charge to attend, but registration is essential.



# DRUG DISCOVERY 2022 SPONSORS

## PARTNERS



AstraZeneca  
astrazeneca.com



AZONetwork  
azonetwork.com



BioStrata  
biostratamarketing.com



British Pharmacological Society  
bps.ac.uk



Drug Discovery World  
ddw-online.com



Drug Target Review  
drugtargetreview.com



EDIS  
edisgroup.org



GSK  
gsk.com



IBI Journal  
international-biopharma.com



MSD  
msd.com



Organoid Spheroid  
organoidspheroid.com

RSK Life  
Science Media

RSK-Solutions  
linkedin.com/in/rizwanc



Royal Society of Chemistry  
rsc.org



SILA  
sila-standard.com



SLAS  
slas.org

## PLATINUM SPONSORS



10x Genomics  
10xgenomics.com



Bio-Rad  
bio-rad.com



bit.bio  
bit.bio



Genedata  
genedata.com



Nexcelom Bioscience  
nexcelom.com

## INDUSTRY INSIDERS



Beckman Coulter  
beckman.com



Charnwood Molecular  
charnwood-molecular.com



Ncardia  
ncardia.com



Oxford Nanopore Technologies  
nanoporetech.com



Peak Proteins  
peakproteins.com



Pelago Bioscience  
pelagobio.com



Synthego  
synthego.com



WuXi AppTec  
wuxiapptec.com

# DRUG DISCOVERY 2022 SPONSORS

## GOLD SPONSORS



Automata  
automata.tech



Avantor Sciences  
avantorsciences.com



Azenta Life Sciences  
azenta.com



BMG LABTECH  
bmglabtech.com



Cytek Biosciences  
cytekbio.com



Formulatrix  
formulatrix.com



Fortis Life Sciences  
fortislife.com



Greiner Bio One  
gbo.com



Hamilton  
hamiltoncompany.com



Integra Biosciences  
integra-biosciences.com



Lablogic Systems  
lablogic.com



Miltényi  
miltényibiotec.com



MolGen  
molgen.com



Tecan  
tecan.com



Twist Bioscience  
twistbioscience.com

## BRONZE SPONSORS



Araceli Biosciences  
aracelibio.com



Benchling  
benchling.com



Cellenion  
cellenion.com



Eurofins Discovery  
eurofinsdiscoveryservices.com



FESTO  
festo.com



Fida Biosystems  
fidabio.com



HexagonFab  
hexagonfab.com



HUB Organoids  
huborganoids.nl



LGC - ATCC  
lgcstandards-atcc.org



Promega  
promega.co.uk



Standard Bio  
standard.bio



Takara Bio Europe  
takarabio.com

# DRUG DISCOVERY 2022 EXHIBITORS

## STANDARD SPONSORS

**abcam**

Abcam  
abcam.com

**Acro**  
BIOSYSTEMS

ACROBiosystems  
acrobiosystems.com

**Agilent**

Agilent Technologies  
agilent.com

**amsbio**

AMSBIO  
amsbio.com

**APCONIX**  
a better decision

Apconix  
apconix.com

**AstraZeneca**

AstraZenca  
openinnovation.  
astrazeneca.com

**atelerix**

Atelerix  
atelerix.co.uk

**AXOL**  
Discovery Stems From Here

Axol Bioscience Ltd  
axolbio.com

**BD**

BD Biosciences  
bdbiosciences.com

**bio:ascent**

BioAscent  
bioascent.com

**BIOCAIR**  
MOVING SCIENCE FORWARD

Biocair  
biocair.com

**BIOIVT**  
ELEVATING SCIENCE

BioIVT  
bioivt.com

**Biorelate**

Biorelate  
biorelate.com

**BIOSERO**

BioSero  
biosero.com

**biotechne**

Bio-Techne  
bio-technique.com

**BLUE CAT BIO**

BlueCatBio  
bluecatbio.com

**bms**  
bio molecular systems

Bio Molecular Systems Ltd  
biomolecularsystems.com

**BRUKER**

Bruker  
bruker.com

**Caltag Medsystems**  
life science solutions

Caltag Medsystems  
caltagmedsystems.co.uk

**cambridge bioscience**

Cambridge Bioscience  
bioscience.co.uk

**CANCER RESEARCH HORIZONS**  
FURTHER FASTER TOGETHER

Cancer Research Horizons  
cancerresearchhorizons.com

**carterra**

Carterra  
carterra-bio.com

**CBRE**

CBRE Integrated  
Laboratory Solutions  
cbre.com

**Cell Signaling TECHNOLOGY**

Cell Signaling Technology  
cellsignal.com

**CELLBOX**

Cellbox Solutions  
cellbox-solutions.com

**CELLINK**  
LIFE SCIENCES

CELLINK  
cellink.com

**CN-BIO**

CN-Bio  
cn-bio.com

**CDD.VAULT**  
Complexity Simplified

Collaborative Drug  
Discovery  
collaborativedrug.com

**Core Life Analytics**

Core Life Analytics  
corelifeanalytics.com

**CORNING**

Corning Life Sciences  
corning.com/lifesciences

**Creoptix**  
A Malvern Panalytical brand

Creoptix  
creoptix.com

**CYTENA**  
A BICO COMPANY

CYTENA  
cytena.com

**CRYONISS**

Cryoniss  
cryoniss.com

**DISPENDIX**  
A BICO COMPANY

Dispendix  
dispendix.com

**DIVERSA**

DIVERSA Technologies  
diversatechnologies.com

**ECACC**  
European Collection  
of Authenticated  
Cell Cultures

The European Collection of  
Authenticated Cell Cultures  
culturecollections.org.uk

# DRUG DISCOVERY 2022 EXHIBITORS



Elemental Machines  
elementalmachines.com



Fios Genomics  
fiosgenomics.com



Flexible Lab Solutions  
flexible-lab-solutions.co.uk



Flow Robotics  
flow-robotics.com



Fritz Gyger AG  
fgyger.ch



Fusion Antibodies  
fusionantibodies.com



Gilson  
gb.gilson.com



Hamilton Storage  
hamiltoncompany.com



HORIBA  
horiba.com



IDBS  
idbs.com



Iktos  
iktos.ai




Innoprot  
innoprot.com



IotaSciences  
iotasciences.com



LifeArc  
lifeArc.org



Medicilon  
medicilon.com



MedChemExpress  
medchemexpress.com



Medicines Discovery Catapult  
md.catapult.org.uk



Newcells Biotech  
newcellsbiotech.co.uk



Organoid Spheroid  
organoidspheroid.com



PeproTech  
peprotech.com



Pharmaron  
pharmaron.com



Proteintech  
ptglab.com



Proteome Sciences Plc  
proteomics.com



Sengenics  
sengenics.com



Stemcell  
stemcell.com



Strattech Scientific  
strattech.co.uk



SUN Bioscience  
sunbioscience.ch



TargetMol  
targetmol.com



Thermo Fisher Scientific  
thermofisher.com



UPM  
upmbiomedicals.com



Veon Scientific  
veonscientific.com



Yokogawa Deutschland  
yokogawa.com



Ziath  
ziath.com

# DRUG DISCOVERY 2022 EXHIBITORS

## LEARNING ZONE



Scientific Solutions  
Recruitment  
[sciencesolutionsrecruitment.com](https://sciencesolutionsrecruitment.com)



LifeArc  
[lifearc.org](https://lifearc.org)



Singular Talent  
[singular talent.io](https://singular talent.io)



AstraZeneca  
[astrazeneca.com](https://astrazeneca.com)



ECP Meet & Greet  
[www.elrig.org/early-career-professionals](https://www.elrig.org/early-career-professionals)



GSK  
[gsk.com/en-gb/careers](https://gsk.com/en-gb/careers)



Royal Society of Chemistry  
[rsc.org](https://rsc.org)



MSD  
[msd.com](https://msd.com)



Langton Howarth  
[langtonhowarth.co.uk](https://langtonhowarth.co.uk)



Zyme  
[zymecommunications.com](https://zymecommunications.com)

## SLAS INNOVATIONS AveNEW



Pharmacelera  
[pharmacelera.com](https://pharmacelera.com)



Salve Therapeutics  
[salvetx.com](https://salvetx.com)



Navigate Precision Biology  
[precision-biology.com](https://precision-biology.com)



EXIT071  
[exit071.com](https://exit071.com)



Inventia Life Science  
[inventia.life](https://inventia.life)



JOIN US FOR A  
**CELEBRATION OF  
DRUG DISCOVERY**  
SPONSORED BY SYNTHEGO

SYNTHEGO

4TH OCTOBER 2022, 19.00  
AT THE FOX, ExCeL

